Blood Pressure Pills Fail – Nationwide Recall

Pills with warning sign in background — Photo: Teacher Photo / Shutterstock

A common blood pressure pill was recalled twice in three months because some tablets may not dissolve or work properly.

Story Snapshot

Two nationwide recalls hit chlorthalidone 25 mg tablets in June and September.
The September action covers 13,567 bottles from batch RISA24002, expiring April 2027.
The issue is failed dissolution testing, which can reduce blood pressure control.
The Food and Drug Administration (FDA) marked the September recall Class II on Sept. 17.

What Was Recalled, When, and Why It Matters

Inventia Healthcare initiated a first recall on June 5, 2026 for 11,460 bottles of chlorthalidone tablets, 25 milligrams, after the product failed dissolution specifications, which means the pills may not break down as intended in the body.

A second, larger recall started on Sept. 3, 2026, covering 13,567 bottles for the same reason. Both recalls were nationwide. Chlorthalidone is a prescription diuretic that doctors use to help lower blood pressure.

The FDA classified the Sept. 3 recall as Class II on Sept. 17, which signals a risk of temporary or medically reversible effects and a remote chance of serious harm.

That language sounds technical, but the takeaway is simple: if a tablet does not dissolve right, the body may absorb less medicine, and blood pressure may not fall as expected. The concern is effect, not contamination. Regulators move fast on this because steady blood pressure control protects the heart, kidneys, and brain.

The Scope: Lots, Bottles, and Expiration Dates

Reports identify the affected September batch as RISA24002 with an April 2027 expiration date and in 100-count bottles. The June event covered 11,460 bottles and included both 100- and 1,000-count packaging in some coverage, pointing to a broad distribution footprint across the country.

Several outlets say the recalls were nationwide, which means patients could have received these pills at many pharmacies, not just a single chain or region.

Media reports note that no injuries or adverse events were reported at the time of coverage, which matches what often happens with dissolution failures; the risk comes from reduced effect, which can be subtle in the short term. That said, poor control can add up.

People who rely on chlorthalidone to keep numbers in range should make sure their bottles are not from the listed batch. If they are, the pharmacy can guide a safe exchange without skipping doses.

Widely used blood pressure medication recalled nationwide https://t.co/Y3YjWnZsOZ #FoxBusiness

— Greg Shields (@GregShield83077) September 30, 2026

How Dissolution Failures Undercut Blood Pressure Control

Dissolution testing checks how fast and how fully a tablet breaks apart in a controlled setting that mimics the gut. When a batch fails, the pill may dissolve too slowly or not enough. That can lower the amount of drug that reaches the bloodstream.

For a blood pressure medicine, lower exposure may mean higher readings and more strain on blood vessels over time. This is why the FDA treats dissolution misses as serious enough to recall, even when severe harm is unlikely.

⚠️ Blood pressure medication recall: More than 25,000 bottles of chlorthalidone have been recalled after failing dissolution tests, which could affect how much medicine is absorbed. Check your medication before taking it. #PoisonHelp 1-800-222-1222https://t.co/wHVuzXVCwJ

— FL Poison Control (@FloridaPoison) September 29, 2026

Practical advice follows two tracks. Patients should not stop their blood pressure medicine on their own. They should check the bottle for the drug name, strength, and lot, then call the pharmacy or prescriber if it matches the recall.

Pharmacists handle exchanges and can coordinate with doctors if a switch is needed. Clinicians may suggest a home blood pressure check plan to confirm control during the transition, since the goal is steady numbers with no gaps in therapy.

Accountability, Quality, and What Comes Next

Two recalls in one summer for the same product raise fair questions about manufacturing controls. Dissolution depends on formula, granulation, compression force, and coating. A slip in any step can change how a tablet behaves in the body.

Media reports link both recalls to the same cause, failed dissolution specifications, which points to a process or method issue that demands a tight corrective and preventive action plan and clear follow-up with the FDA.

Class II recalls can confuse the public because the term sounds urgent while the FDA says the chance of serious harm is remote. The right balance is firm but calm. Consumers deserve medicine that meets the label every time.

Manufacturers must test, catch, and fix problems before pills reach patients. Regulators should keep recall notices clear, with lot numbers up front and plain steps for returns.